Recent News

• 03.28.2025 - Bio-Path Holdings Reports Full Year 2024 Financial Results
• 03.18.2025 - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
• 02.13.2025 - Bio-Path Holdings Expands Global Patent Portfolio
• 02.13.2025 - Bio-Path Holdings Expands Global Patent Portfolio
• 02.13.2025 - Bio-Path Holdings Provides Key Clinical Updates
• 02.13.2025 - Bio-Path Holdings Provides Key Clinical Updates
• 02.12.2025 - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
• 02.12.2025 - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
• 02.12.2025 - SEC Form S-1/A
• 02.12.2025 - SEC Form S-1/A

Recent Filings

• 03.28.2025 - EX-99.1 EX-99.1
• 03.28.2025 - 8-K Current report
• 03.28.2025 - 8-K Current report
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.19.2025 - 8-K Current report
• 03.07.2025 - 8-K Current report
• 02.18.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - S-1/A General form for registration of securities under the Securities Act of 1933